Navigation Links
Michael J. Fox Foundation PD Therapeutics Conference
Date:8/7/2008

The Michael J. Fox Foundation for Parkinson's Research (MJFF) will host its second annual PD Therapeutics Conference on Monday, September 15, in Chicago.

Chaired by Jeffrey Kordower, PhD, Director, Research Center for Brain Repair and Jean-Schweppe Armour Professor of Neurological Sciences at Rush University Medical Center, the conference will bring together academic and industry scientists to focus on novel research advances impacting development of improved disease-modifying and symptomatic interventions for the diagnosis and treatment of PD.

Select MJFF-funded investigators will present research on topics including novel neuroprotective agents, innovative mechanisms to address disease symptoms and improvements in relevant animal models, and biomarker discovery/development.

In addition to scientific talks, a small poster session will highlight novel targets and animal models relevant to PD research.

Confirmed speakers include:

  • D. James Surmeier, PhD (Northwestern University), on the FDA-approved diabetes drug that may protect dopamine neurons in the Parkinson's brain

  • Anders Bjrkund, MD, PhD (Lund University, Sweden), on the role of serotonin (better known for the part it plays in depression) in dyskinesias, the disruptive movements brought on by long-term dopamine replacement therapy

  • Erwan Bezard, PhD (Universite Victor Segalen, Bordeaux, France), and Piu Chan, MD, PhD (Beijing Institute of Geriatrics, China), on conducting pre-clinical and clinical research in China

  • Patrik Brundin, MD, PhD (Lund University, Sweden), on the state of cell replacement approaches for Parkinson's disease

Registration is free for accredited members of the press.

Last year's inaugural conference in New York City drew a multidisciplinary audience of nearly 200 academic, pharmaceutical and biotechnology industry researchers.


'/>"/>

Contact: Holly Barkhymer
hbarkhymer@michaeljfox.org
212-509-0995 x242
The Michael J. Fox Foundation for Parkinson's Research
Source:Eurekalert

Page: 1

Related biology news :

1. [video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.nets 3-Minute Press Show
2. Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinsons Disease
3. Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinsons
4. Neuroscientist Michael Gazzaniga awarded Humboldt Prize
5. Remarks Prepared for Delivery By Attorney General Michael B. Mukasey At the Ministerial Press Conference
6. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
7. American Society for Microbiology honors Michael Bruce Zwick
8. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
9. W.M. Keck Foundation grant funds reproductive science research
10. W.M. Keck Foundation announces 2008 class of Distinguished Young Scholars in Medical Research
11. Glenn Foundation for Medical Research commits $5 million to study aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: